The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Negar Ashouri et al.|Contemporary Clinical Trials|2019Cited by 25
Examination of Adverse Reactions After COVID-19 Vaccination Among Patients With a History of Multisystem Inflammatory Syndrome in ChildrenMatthew D. Elias, Amanda Marshall, Dongngan T. Truong et al.|JAMA Network Open|2023Cited by 16
Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in ChildrenMary Beth F. Son, Leora R. Feldstein, Laura Berbert et al.|JAMA Network Open|2022Cited by 11
CMR Findings in the Long-Term Outcomes After Multisystem Inflammatory Syndrome in Children (MUSIC) StudySean M. Lang, Lauren DiStefano, Dongngan T. Truong et al.|Circulation Cardiovascular Imaging|2025Cited by 4
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki diseaseSamantha C. Roberts, Sylvia H. Yeh, Sonia Jain et al.|Author eBooks|2019Cited by 1